ArticleJournal of Crohn's & colitis2022

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.

Philip J Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.